This is the authors' abstract. We don't add key points for this paper.
This study identified a molecular mechanism contributing to KRAS*-driven colorectal cancer progression via fibroblast transformation in the tumor microenvironment to produce VEGFA driving tumor angiogenesis. In preclinical models, targeting the KRAS*-TFCP2-VEGFA axis impaired tumor progression, revealing a potential novel therapeutic option for patients with KRAS*-driven colorectal cancer. This article is featured in Selected Articles from This Issue, p. 2489.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Hsu et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: